Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 4
1998 5
1999 9
2000 10
2001 14
2002 7
2003 13
2004 10
2005 14
2006 11
2007 11
2008 24
2009 25
2010 21
2011 19
2012 21
2013 18
2014 14
2015 11
2016 25
2017 22
2018 18
2019 23
2020 17
2021 23
2022 25
2023 22
2024 15
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

407 results

Results by year

Filters applied: . Clear all
Page 1
Intranasal Olopatadine-Mometasone in the Treatment of Seasonal Allergic Rhinitis.
Lim L, Lipari M, Kale-Pradhan P. Lim L, et al. Ann Pharmacother. 2023 May;57(5):570-578. doi: 10.1177/10600280221124230. Epub 2022 Sep 19. Ann Pharmacother. 2023. PMID: 36123818 Review.
OBJECTIVE: To review the pharmacology, efficacy, and safety of intranasal olopatadine hydrochloride-mometasone furoate (OM) combination in the treatment of seasonal allergic rhinitis (SAR). DATA SOURCES: The PubMed database and ClinicalTrials.gov were searche …
OBJECTIVE: To review the pharmacology, efficacy, and safety of intranasal olopatadine hydrochloride-mometasone furoate …
Effectiveness of Intranasal Mometasone Furoate vs Saline for Sleep-Disordered Breathing in Children: A Randomized Clinical Trial.
Baker A, Grobler A, Davies K, Griffiths A, Hiscock H, Kubba H, Peters RL, Ranganathan S, Rimmer J, Rose E, Rowe K, Simpson CM, Davidson A, Nixon G, Perrett KP. Baker A, et al. JAMA Pediatr. 2023 Mar 1;177(3):240-247. doi: 10.1001/jamapediatrics.2022.5258. JAMA Pediatr. 2023. PMID: 36648937 Free PMC article. Clinical Trial.
OBJECTIVE: To determine whether intranasal mometasone furoate is more effective than intranasal saline for improving symptoms and quality of life in children with SDB. ...INTERVENTIONS: Participants were randomly assigned to receive mometasone …
OBJECTIVE: To determine whether intranasal mometasone furoate is more effective than intranasal saline for impro …
Allergic Rhinitis: A Review.
Bernstein JA, Bernstein JS, Makol R, Ward S. Bernstein JA, et al. JAMA. 2024 Mar 12;331(10):866-877. doi: 10.1001/jama.2024.0530. JAMA. 2024. PMID: 38470381 Review.
In addition, first-line treatment for mild intermittent or mild persistent allergic rhinitis may include a second-generation H1 antihistamine (eg, cetirizine, fexofenadine, desloratadine, loratadine) or an intranasal antihistamine (eg, azelastine, olopatadine), whereas pat …
In addition, first-line treatment for mild intermittent or mild persistent allergic rhinitis may include a second-generation H1 antihistamin …
Local and systemic safety of intranasal corticosteroids.
Sastre J, Mosges R. Sastre J, et al. J Investig Allergol Clin Immunol. 2012;22(1):1-12. J Investig Allergol Clin Immunol. 2012. PMID: 22448448 Free article. Review.
The safety and efficacy of intranasal corticosteroids (INCs) are well established for the management of allergic rhinitis, rhinosinusitis, and nasal polyps. ...A review of the published literature indicates that the side effect profiles of INCs consist primarily of a low i …
The safety and efficacy of intranasal corticosteroids (INCs) are well established for the management of allergic rhinitis, rhinosinus …
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, Sousa AR, Chan R, Hopkins C; SYNAPSE study investigators. Han JK, et al. Lancet Respir Med. 2021 Oct;9(10):1141-1153. doi: 10.1016/S2213-2600(21)00097-7. Epub 2021 Apr 16. Lancet Respir Med. 2021. PMID: 33872587
Patients were randomly assigned (1:1), using permuted block design, to receive either 100 mg mepolizumab subcutaneously or placebo once every 4 weeks, in addition to standard of care (mometasone furoate intranasal spray for at least 8 weeks before screening a …
Patients were randomly assigned (1:1), using permuted block design, to receive either 100 mg mepolizumab subcutaneously or placebo once ever …
Intranasal corticosteroid and antihistamine combinations in the treatment of allergic rhinitis: the role of the novel formulation olopatadine/mometasone furoate.
Ridolo E, Barone A, Nicoletta F, Paoletti G, Heffler E, Malvezzi L, Canonica GW. Ridolo E, et al. Expert Rev Clin Immunol. 2023 Jun;19(6):575-584. doi: 10.1080/1744666X.2023.2200165. Epub 2023 Apr 19. Expert Rev Clin Immunol. 2023. PMID: 37038974 Review.
AREAS COVERED: GSP301 (olopatadine 600 g - mometasone furoate 25 g) is a novel intranasal formulation, combining the second-generation antihistamine olopatadine hydrochloride with mometasone furoate. Here, we review the evidence for GSP301, espe …
AREAS COVERED: GSP301 (olopatadine 600 g - mometasone furoate 25 g) is a novel intranasal formulation, combining the se …
Intranasal combo: fixed-dose combination of mometasone furoate and olopatadine hydrochloride in therapeutic strategies for rhinosinusitis.
Samoliński B, Wojas O, Lipiec A, Krzych-Fałta E, Walkiewicz A, Borowicz J, Samoliński K. Samoliński B, et al. Otolaryngol Pol. 2023 Dec 4;77(6):43-50. doi: 10.5604/01.3001.0054.0941. Otolaryngol Pol. 2023. PMID: 38706259 Free article.
A novel strategy for the treatment of allergic rhinitis results from the innovative combination of antihistamine and intranasal corticosteroid drugs. By combining two preparations with different mechanism of action, this novel approach facilitates quick and effective contr …
A novel strategy for the treatment of allergic rhinitis results from the innovative combination of antihistamine and intranasal corti …
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Gevaert P, et al. J Allergy Clin Immunol. 2020 Sep;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032. Epub 2020 Jun 7. J Allergy Clin Immunol. 2020. PMID: 32524991 Free article. Clinical Trial.
METHODS: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and intranasal mometasone for 24 weeks. ...CONCLUSION: Omalizumab significantly improved endoscopic, clinical, and patient-report …
METHODS: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and …
Mometasone furoate. A review of its intranasal use in allergic rhinitis.
Onrust SV, Lamb HM. Onrust SV, et al. Drugs. 1998 Oct;56(4):725-45. doi: 10.2165/00003495-199856040-00018. Drugs. 1998. PMID: 9806113 Review.
Mometasone furoate is a synthetic corticosteroid which has been evaluated for intranasal use in the treatment of adults and children with allergic rhinitis. ...CONCLUSIONS: Mometasone furoate is a well tolerated intranasal corticosteroid …
Mometasone furoate is a synthetic corticosteroid which has been evaluated for intranasal use in the treatment of adults …
Effect of an Intranasal Corticosteroid on Quality of Life and Local Microbiome in Young Children With Chronic Rhinosinusitis: A Randomized Clinical Trial.
Latek M, Lacwik P, Molinska K, Blauz A, Lach J, Rychlik B, Strapagiel D, Majak J, Molinska J, Czech D, Seweryn M, Kuna P, Palczynski C, Majak P. Latek M, et al. JAMA Pediatr. 2023 Apr 1;177(4):345-352. doi: 10.1001/jamapediatrics.2022.6172. JAMA Pediatr. 2023. PMID: 36848113 Free PMC article. Clinical Trial.
IMPORTANCE: Intranasal corticosteroids (INCs) remain the first-line treatment of chronic rhinosinusitis (CRS) in both adults and children, despite the lack of evidence regarding their efficacy in the pediatric population. ...INTERVENTIONS: Patients were randomized to recei …
IMPORTANCE: Intranasal corticosteroids (INCs) remain the first-line treatment of chronic rhinosinusitis (CRS) in both adults and chil …
407 results